Results 31 to 40 of about 62,277 (245)

Clozapine treatment during the COVID-19 pandemic

European Psychiatry, 2021
Introduction Clozapine is an effective antipsychotic used in treatment-resistant schizophrenia. One of the serious complications of clozapine therapy is agranulocytosis, therefore regular monitoring of the level of white blood cells (WBC) in plasma is ...
E. Dąbrowska, B. Galińska-Skok, D. Zalewski, A. Nobis   +3 more
doaj   +1 more source

Thalamic inputs to dorsomedial striatum are involved in inhibitory control: evidence from the five-choice serial reaction time task in rats [PDF]

, 2017
Rationale Corticostriatal circuits are widely implicated in the top-down control of attention including inhibitory control and behavioural flexibility. However, recent neurophysiological evidence also suggests a role for thalamic inputs to striatum in
A Bari, A Castañé, BN Armbruster, D Dautan, EA Schilman, ER Murphy, ES Robinson, G Paxinos, GM Alexander, HD Brown, J Groenewegen, J Wess, JN Rouder, JW Dalley, K Guillem, KM Turner, LA Bradfield, M Baviera, M Bentivoglio, M Carli, M Kimura, M Pezze, ME Ragozzino, N Amitai, N Matsumoto, NM Doig, P Aldrin-Kirk, RD Rogers, S Kinomura, SV Mahler, T Minamimoto, T Robbins, TJ Stachniak, TW Faust, V Boulougouris, Y Chudasama, Y Smith   +36 more
core   +2 more sources

Change in plasma concentration of clozapine and norclozapine following a switch of oral formulation

Therapeutic Advances in Psychopharmacology, 2020
Background: Clozapine formulation has been shown to affect plasma concentrations of clozapine and norclozapine. Changes in formulation might result in toxicity or treatment failure.
Farinaz Keshavarzi, Tony Fox, Eromona Whiskey, David Taylor   +3 more
doaj   +1 more source

Factors predicting serum clozapine levels in Middle Eastern patients: an observational study

BMC Psychiatry, 2022
Background Despite its superiority over other drugs for psychosis, clozapine remains underused and is associated with many clinical challenges, including difficulties in predicting therapeutic serum levels (350-600 ng/mL).
Ahmed Hassab Errasoul, Mohammed A. Alarabi   +1 more
doaj   +1 more source

Metabotropic glutamate 2/3 receptors and epigenetic modifications in psychotic disorders: a review [PDF]

, 2016
Schizophrenia and Bipolar Disorder are chronic psychiatric disorders, both considered as "major psychosis"; they are thought to share some pathogenetic factors involving a dysfunctional gene x environment interaction.
Grayson, Danis R, Guidotti, Alessandro, MATRISCIANO, FRANCESCO, NICOLETTI, Ferdinando, PANACCIONE, ISABELLA   +4 more
core   +2 more sources

An evaluation of subjective experiences, effects and overall satisfaction with clozapine treatment in a UK forensic service [PDF]

, 2015
Objectives: Patients prescribed clozapine were surveyed to assess (a) the effects, both positive and adverse, and overall satisfaction with clozapine in comparison to previously prescribed antipsychotics and (b) the relative significance of effects ...
Chaudhry, I., Chu, S., Duffy, C., Husain, N., Qurashi, I., Stephenson, P.   +5 more
core   +1 more source

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database [PDF]

, 2013
Background: Drug-induced torsades de pointes (TdP) and related clinical entities represent a current regulatory and clinical burden. Objective: As part of the FP7 ARITMO (Arrhythmogenic Potential of Drugs) project, we explored the publicly available US ...
A Bate, A Clarke, A Pariente, AK Chung, Ariola Koci, B Darpo, BJ Drew, C Meyer-Massetti, DM Roden, DW Hough, E Poluzzi, E Poluzzi, E Poluzzi, E Raschi, E Raschi, Edoardo Spina, Elijah R. Behr, Elisabetta Poluzzi, Emanuel Raschi, EP Puijenbroek van, ER Behr, F Ponti De, F Ponti De, F Rani, Fabrizio De Ponti, GC Alexander, GK Isbister, H Verdoux, J Nielsen, J Papay, K Jolly, K Titier, LC Wittkampf, LS Schneider, Miriam Sturkenboom, NP Tatonetti, P Kannankeril, P Manu, P Vigneault, RC Owens Jr, RR Shah, S Dhillon, S Hennessy, S Kongsamut, S Leucht, SM Straus, Ugo Moretti, W Crumb, W Crumb, WA Ray, WA Ray, WJ Crumb Jr, WP Stephenson, Y Suzuki   +53 more
core   +4 more sources

Potential Indicators of Bone Marrow Suppression in Patients with Schizophrenia Receiving Clozapine: Platelet-Large Cell Ratio and Immature Granulocytes

Psychiatry and Behavioral Sciences
Aim/background: The use of clozapine is restricted due to its serious side effects, particularly bone marrow suppression, which occurs at an average rate of 1%.
Hatice Saracoğlu, Ciğdem Karakukcu, Canan Kılıc, Yasemin Şimşek   +3 more
doaj   +1 more source

A case of hypotension and heart rate changes on rechallenge with a low dose of clozapine with no apparent secondary cause

Sri Lanka Journal of Psychiatry, 2022
Clozapine is known to cause innocuous as well as severe and or fatal cardiovascular side effects. These side effects are commonly reported at the initiation of clozapine therapy.
M. L. Harshini, A. I. W. Fernando, H. M. T. S. Abayawickrama, M. I. N. Ikram, S. Rajapakse, A. Hapangama   +5 more
doaj   +1 more source

Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations

Therapeutic Advances in Psychopharmacology, 2021
Background: Clozapine is the only medication licenced for treating patients with treatment-refractory schizophrenia. However, there are no evidence-based guidelines as to the optimal plasma level of clozapine to aim for, and their association with ...
Amir Krivoy, Eromona Whiskey, Henrietta Webb-Wilson, Dan Joyce, Derek K. Tracy, Fiona Gaughran, James H. MacCabe, Sukhwinder S. Shergill   +7 more
doaj   +1 more source